Our October issue is live!
Welcome to this week's edition of Dermatology Times' LinkedIn newsletter!
We're excited to share that our October issue is now live on our website. Starting this week, we will begin sharing insights and articles from the issue on our website and social media channels. In the meantime, we invite you to visit our website to download and explore the issue, which features insights into non-invasive treatment modalities for squamous cell carcinoma, changing perceptions of medical aesthetics, and more. If you haven't yet subscribed to receive physical copies of our publication, we invite you to do so here.
If you have questions, suggestions, or would like to contribute to a future edition, please contact us via LinkedIn or via email at [email protected].
?? Breaking News Brief
优时比 announced the start of the BE BOLD phase 3b clinical trial, which will compare the efficacy of bimekizumab (Bimzelx) against risankizumab (Skyrizi) in adults with active psoriatic arthritis. This trial is the first to evaluate an IL-17A and IL-17F inhibitor, bimekizumab, versus an IL-23 inhibitor, risankizumab, in this population. The study will assess ACR50 response at week 16, and results are expected by 2026.
?? Research Roundup
A late-breaker presentation at the 33rd EADV Congress detailed the 40-week results of a phase 2 study evaluating the safety and efficacy of oral povorcitinib, a JAK1 inhibitor, for treating prurigo nodularis. The study, following a successful 16-week dose-ranging phase, showed that patients receiving povorcitinib experienced significant itch relief and improved IGA scores. At week 16, more patients on povorcitinib achieved a ≥4-point improvement in itch severity compared to placebo, with the 75mg dose showing the fastest response.
A recent multicenter study assessed the use of the Alexandrite laser (755 nm) for treating pigmented actinic keratoses. The study, involving 50 patients, showed significant improvement in pigmentation, with no severe adverse effects. The median pigmentation score improved, and nearly half of the lesions demonstrated high efficacy. Researchers concluded that the Alexandrite laser is an effective and well-tolerated option for treating PAKs.
Results from the ECZTEND trial revealed that over 70% of patients with atopic dermatitis who continued treatment with tralokinumab (Adbry; LEO Pharma ) maintained a stable EASI score ≤ 7 for at least 80% of the days. The trial is a 5-year extension of the phase 3 ECZTRA 1 and 2 trials, involving 347 patients.
?? Expert Insights
Explore clinical insights from: Jason Hawkes, MD; Patrick Burnett, MD, PhD, FAAD; and Gil Yosipovitch, MD.
?? Skin In The News
?? Continuing Education Opportunities
Discover ways to further your education and knowledge of specific disease states by exploring CME opportunities from Physicians' Education Resource?, LLC (PER?) below.
For more information, visit PER's website or click on the graphics below.
Thank you for reading!